Abstract 181P
Background
There are no standardised, recognised regimens for third line treatment of advanced pancreatic cancer, with most clinicians using best supportive care in this scenario. Gemcitabine plus nab-paclitaxel and FOLFIRINOX are non-cross resistant regimens. This generates the hypothesis that patients who responded well in the first line setting to gemcitabine and nab-paclitaxel could respond again if rechallenged in the third line setting, after second line FOLFIRINOX.
Methods
A retrospective analysis was conducted via an electronic database from two of our institutions, of locally advanced or metastatic pancreatic adenocarcinoma patients who were treated with gemcitabine plus nab-paclitaxel both as a first line and third line chemotherapy regimen between January 2013 and July 2019. All patients had an ECOG performance status of 2 or less. Overall survival (OS) was estimated by the Kaplan-Meier method.
Results
We identified 30 patients in our analysis. 63% of the patients were female, with the median age of all patients at diagnosis being 67 (range, 38 – 82). 60% of the studied patients had locally advanced disease at diagnosis. Median OS from diagnosis was 39.0 months (95% CI, 34.0 – 66.0). Median OS from third-line re-initiation of gemcitabine plus nab-paclitaxel was 29.0 months (95% CI, 9.0 – 36.0).
Conclusions
Patient who maintain a good performance status after second line treatment present a management dilemma, as these patients are often reluctant to accept best supportive care when they feel well enough to tolerate another line of chemotherapy. The median OS (29 months) and age (67) is surprising, but probably represents the selection bias of patients who retain sufficient performance status to undergo third line therapy. Patients who have receive first line gemcitabine plus nab-paclitaxel, and second line FOLFIRINOX whilst maintaining good performance status, should be considered for re-treatment with gemcitabine plus nab-paclitaxel, as evidenced by our data from two of our institutions. Phase III studies would be highly beneficial to further investigate this as a potential standard of care for third-line treatment in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
St John of God Hospital Subiaco.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract